This randomized managed trial offers sturdy proof supporting the therapeutic
efficacy and security profile of transdermal THC:CBD:CBN formulation within the administration of painful diabetic peripheral neuropathy. The demonstrated vital discount in
multidimensional ache scores, mixed with the pharmacokinetic benefits of transdermal supply and favorable security outcomes, suggests substantial scientific potential for this therapeutic strategy. Because the proof base continues to develop, cannabinoid-based interventions could emerge as a helpful therapeutic possibility in addressing the complicated challenges of neuropathic ache administration.
